dimethyl-(2-nitro-[1]naphthyl)-amine | 39139-77-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: dimethyl-(2-nitro-[1]naphthyl)-amine
• 英文别名: Dimethyl-(2-nitro-[1]naphthyl)-amin；2-Nitro-1-dimethylamino-naphthalin；dimethyl-(2-nitro-naphthalen-1-yl)-amine；N,N-dimethyl-2-nitronaphthalen-1-amine
• CAS: 39139-77-0
• 化学式: C₁₂H₁₂N₂O₂
• 分子量: 216.239
• InChiKey: PNKBSLRSYFNXOZ-UHFFFAOYSA-N

物化性质

• 沸点：
  338.6±25.0 °C(Predicted)
• 密度：
  1.247±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  49.1
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  dimethyl-(2-nitro-[1]naphthyl)-amine 在 alkaline solution 作用下， 生成 2-硝基-1-萘酚
  参考文献：
  名称：

  Vesely; Vojtech, Collection of Czechoslovak Chemical Communications, vol. 1, p. 111

  摘要：

  DOI：
• 作为产物：
  描述：

  二硝基萘(混合物) 、 二甲胺 生成 dimethyl-(2-nitro-[1]naphthyl)-amine
  参考文献：
  名称：

  A comparative study between excess-dose users and regular-dose users of rhubarb contained in Kampo medicines

  摘要：

  With prolonged use of rhubarb-containing Kampo medicines, some patients come to ask for highdose rhubarb because of deteriorated reactivity to rhubarb. We divided patients into two groups in terms of rhubarb-dose, and compared clinical backgrounds between regular-dose group and excess-dose group. Patients who were treated with rhubarb-containing Kampo extracts (manufactured prescriptions) or Kampo formulae (decoctions) for more than 12 months were enrolled. These two groups were compared for age, sex, shape of stool, abdominal symptoms, existence of hemorrhoids, Kampo diagnosis of abdomen, past stimulant laxative use, duration of stimulant laxative use before the first administration of rhubarb, duration of rhubarb use in our hospital, and initial existence of stimulant pain caused by taking stimulant laxatives for the first time. No significant difference was shown between the two groups in terms of age, duration of stimulant laxative-use before the first prescription of rhubarb, shape of stool, abdominal symptoms, existence of hemorrhoids, or duration of rhubarb-use. However, most patients in the regular-dose group had initial stimulant pain of the abdomen upon taking stimulant laxatives for the first time, but most patients in the excess-dose group did not (p < 0.001). All patients except one in the regular dose group had the sign of "umbilical region tenderness on pressure", but half of the excess-dose group did not have it (P = 0.041). Based on these findings, the absence of "initial stimulant pain" and the absence of "umbilical region tenderness on pressure" may predict increasing or excess use of rhubarb, and long-term use of rhubarb should be discouraged more strongly in the patients without these signs.

  DOI：

  10.1078/09447110260571580

文献信息

• 1,2-Substituted naphthalene derivatives with antiglutamatergic properties and uses thereof
  申请人：Faust Pharmaceuticals

  公开号：EP1777219A1

  公开（公告）日：2007-04-25

  The present invention provides new compounds displaying antiglutamatergic properties. It also provides the use of such compounds for the treatment and/or prophylaxis of conditions and diseases linked to abnormalities in glutamatergic transmission. It further provides a pharmaceutical composition for the treatment and/or prophylaxis of acute and chronic neurodegenerative conditions and disorders.

  本发明提供了显示抗谷氨酸能作用的新化合物。它还提供了利用这些化合物治疗和/或预防与谷氨酸传递异常相关的疾病和病症。此外，还提供了一种用于治疗和/或预防急性和慢性神经退行性病症和紊乱的药物组合物。
• Vesely; Vojtech, Collection of Czechoslovak Chemical Communications, vol. 1, p. 111
  作者：Vesely、Vojtech

  DOI：——

  日期：——
• [EN] NEW COMPOUNDS WITH ANTIGLUTAMATERGIC PROPERTIES AND USES THEREOF<br/>[FR] NOUVEAUX COMPOSES A PROPRIETES ANTIGLUTAMATERGIQUES ET LEURS UTILISATIONS
  申请人：FAUST PHARMACEUTICALS

  公开号：WO2007054836A2

  公开（公告）日：2007-05-18

  [EN] The present invention provides new compounds displaying antiglutamatergic properties. It also provides the use of such compounds for the treatment and/or prophylaxis of conditions and diseases linked to abnormalities in glutamatergic transmission. It further provides a pharmaceutical composition for the treatment and/or prophylaxis of acute and chronic neurodegenerative conditions and disorders.
  [FR] La présente invention concerne de nouveaux composés qui présentent des propriétés antiglutamatergiques. Elle propose aussi l'utilisation de tels composés pour le traitement et/ou la prophylaxie de conditions et de maladies liées aux anormalités de transmission glutamatergique. Elle fournit aussi une composition pharmaceutique pour le traitement et/ou la prophylaxie de conditions et de désordres neurodégénératifs aigus et chroniques.
• A comparative study between excess-dose users and regular-dose users of rhubarb contained in Kampo medicines
  作者：N. Mantani、T. Kogure、S. Sakai、M. Kainuma、Y. Kasahara、A. Niizawa、Y. Shimada、K. Terasawa

  DOI：10.1078/09447110260571580

  日期：2002.1

  With prolonged use of rhubarb-containing Kampo medicines, some patients come to ask for highdose rhubarb because of deteriorated reactivity to rhubarb. We divided patients into two groups in terms of rhubarb-dose, and compared clinical backgrounds between regular-dose group and excess-dose group. Patients who were treated with rhubarb-containing Kampo extracts (manufactured prescriptions) or Kampo formulae (decoctions) for more than 12 months were enrolled. These two groups were compared for age, sex, shape of stool, abdominal symptoms, existence of hemorrhoids, Kampo diagnosis of abdomen, past stimulant laxative use, duration of stimulant laxative use before the first administration of rhubarb, duration of rhubarb use in our hospital, and initial existence of stimulant pain caused by taking stimulant laxatives for the first time. No significant difference was shown between the two groups in terms of age, duration of stimulant laxative-use before the first prescription of rhubarb, shape of stool, abdominal symptoms, existence of hemorrhoids, or duration of rhubarb-use. However, most patients in the regular-dose group had initial stimulant pain of the abdomen upon taking stimulant laxatives for the first time, but most patients in the excess-dose group did not (p < 0.001). All patients except one in the regular dose group had the sign of "umbilical region tenderness on pressure", but half of the excess-dose group did not have it (P = 0.041). Based on these findings, the absence of "initial stimulant pain" and the absence of "umbilical region tenderness on pressure" may predict increasing or excess use of rhubarb, and long-term use of rhubarb should be discouraged more strongly in the patients without these signs.